Sanuwave Announces Revenues and Financial Results for Q1 FY2026

Sanuwave Health (NASDAQ: SNWV) reported Q1 2026 revenues of $9.6 million, up 3.1% from $9.3 million in Q1 2025, marking the highest Q1 quarterly revenue in company history. However, gross margin declined to 77.3% from 79.0% due to wholesale pricing for resellers. The company swung to a $1.1 million operating loss from $0.6 million operating income in the prior year. Management expressed optimism about recovery beginning in February, with consumables unit volumes reaching all-time records. The company guides for Q2 2026 revenue growth of 10-15% and full-year 2026 growth of 16-25%.

05/12/2026, 5:00 PM • GlobeNewswire

Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results

Sanuwave Health, Inc. (NASDAQ: SNWV) announced it will host a conference call on May 13, 2026 at 8:30 AM ET to present Q1 2026 financial results. The company reported preliminary Q1 2026 revenue of $9.6-$9.7 million, representing a 3-4% year-over-year increase.

05/06/2026, 5:00 PM • GlobeNewswire

Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year

Sanuwave Health reported Q1 2026 preliminary revenues of $9.6-$9.7 million, representing 3-4% growth over Q1 2025 and in line with guidance. The company attributed lower-than-midpoint results to deals sliding out of the quarter due to reimbursement changes in the wound care space affecting skin substitutes and allografts. CEO Morgan Frank expressed cautious optimism about market recovery, noting strong interest in Sanuwave's Ultramist product at the SAWC conference.

04/16/2026, 5:00 PM • GlobeNewswire

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

Sanuwave Health announced record Q4 2025 revenues of $13.4 million (up 29.7% YoY) and full year 2025 revenues of $44.1 million (up 35% YoY). The company achieved record quarterly and annual results driven by UltraMist system sales (255 units in Q4, 624 for full year) and consumables revenue growth. Gross margin improved to 77.1% for full year 2025. The company issued Q1 2026 guidance of $9.6-10.3 million (3-10% growth) and full year 2026 guidance of $51.0-55.0 million (16-25% growth).

03/26/2026, 5:00 PM • GlobeNewswire

Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Sanuwave Health, a wound care products company, will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, offering meetings with company management.

12/10/2025, 6:00 AM • GlobeNewswire

Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply

Sanuwave Health has added its UltraMIST product line to Healogics iSupply Group Purchasing Organization, expanding access for wound care centers, home health agencies, and skilled nursing facilities.

12/08/2025, 6:00 AM • GlobeNewswire

CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)

Sanuwave Health announced that CMS's 2026 Physician Fee Schedule for UltraMIST procedure (CPT code 97610) remains largely unchanged, with reimbursement rates staying within $2-4 of 2025 levels.

11/03/2025, 5:00 AM • GlobeNewswire

Stock Market Today: Dow Jones, Nasdaq 100, S&P 500 Futures Turn Green—Trilogy Metals, AMD, Applovin In Focus (UPDATED)

U.S. stock futures fell on Tuesday, with market attention focused on potential Federal Reserve rate cuts and ongoing government shutdown. Key companies like AMD and Trilogy Metals saw significant stock movements due to strategic developments.

10/07/2025, 8:48 AM • Benzinga

Stock Market Today: Dow Jones, Nasdaq Futures Slip Amid Delay In Trade Deficit Data During Shutdown—Trilogy Metals, AMD, Applovin In Focus

U.S. stock futures fell on Tuesday, with market attention focused on potential Federal Reserve rate cuts and ongoing government shutdown. Key companies like AMD and Trilogy Metals saw significant stock movements due to strategic developments.

10/07/2025, 5:48 AM • Benzinga

3 Lesser-Known Healthcare Names With Major Upside in Store

The global healthcare market is expected to grow significantly, with three lesser-known companies showing promising potential: Sanuwave Health, Amneal Pharmaceuticals, and Belite Bio, each offering unique strengths in medical technology and pharmaceuticals.

10/02/2025, 9:06 AM • Investing

Sanuwave Announces Strategic Debt Refinancing with New Credit Facility

Sanuwave Health successfully refinanced its $27.5 million debt facility with NH Expansion by securing a new $24 million credit facility from J.P. Morgan, featuring a $23 million term loan and $5 million revolving credit line at SOFR +350bp with no prepayment penalties.

09/26/2025, 7:00 AM • GlobeNewswire

Sanuwave Announces Q2 FY2025 Financial Results

Sanuwave Health reported Q2 2025 revenues of $10.2 million, a 42% increase from Q2 2024, with 116 UltraMist systems sold. The company is restructuring sales operations and expects momentum in Q3 and Q4 2025.

08/08/2025, 6:00 AM • GlobeNewswire

Sanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial Results

Sanuwave Health will host a conference call on August 8, 2025 at 8:30 AM ET to discuss its Q2 2025 financial results, providing details on dial-in information and a replay option.

08/04/2025, 5:00 PM • GlobeNewswire